NasdaqCM - Nasdaq Real Time Price USD

Beyond Air, Inc. (XAIR)

0.1950

-0.0011

(-0.56%)

At close: 4:00:02 PM EDT

0.1925

-0.00

(-1.28%)

After hours: 6:21:35 PM EDT

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient

GlobeNewswire 18 days ago

XAIR
-0.56%
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026 BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has gran

GlobeNewswire 21 days ago

XAIR
-0.56%
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s DiseaseBOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan S

GlobeNewswire 27 days ago

XAIR
-0.56%
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection” in Annals of the American Thoracic Soc

GlobeNewswire last month

XAIR
-0.56%
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Gr

GlobeNewswire last month

XAIR
-0.56%
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technologyGARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vande

GlobeNewswire last month

XAIR
-0.56%
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Al

GlobeNewswire last month

XAIR
-0.56%
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives o

GlobeNewswire 2 months ago

XAIR
-0.56%
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technolo

GlobeNewswire 2 months ago

XAIR
-0.56%
Beyond Air Third Quarter 2025 Earnings: Beats Expectations

Beyond Air ( NASDAQ:XAIR ) Third Quarter 2025 Results Key Financial Results Revenue: US$1.07m (up 174% from 3Q 2024...

Simply Wall St. 2 months ago

XAIR
-0.56%
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing

GlobeNewswire 2 months ago

XAIR
-0.56%
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s mi

GlobeNewswire 3 months ago

XAIR
-0.56%
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monday, February 10, 2025 after the market closes. Conference Call & WebcastMonday, February 10th @ 4:30 PM

GlobeNewswire 3 months ago

XAIR
-0.56%
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the LungFit® PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the devic

GlobeNewswire 3 months ago

XAIR
-0.56%
Insider Stock Buying Reaches US$1.60m On Beyond Air

Over the last year, a good number of insiders have significantly increased their holdings in Beyond Air, Inc...

Simply Wall St. 3 months ago

XAIR
-0.56%
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monda

GlobeNewswire 4 months ago

XAIR
-0.56%
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four

GlobeNewswire 5 months ago

XAIR
-0.56%
Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacific partner, Getz Healthcare GARDEN CITY, N.Y., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitri

GlobeNewswire 5 months ago

XAIR
-0.56%
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disordersDUBLIN and GARDEN CITY, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Professor Roger D. Kornb

GlobeNewswire 5 months ago

XAIR
-0.56%
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024 i

GlobeNewswire 5 months ago

XAIR
-0.56%

Performance Overview

Return	XAIR	S&P 500 (^GSPC)
YTD	-45.68%	-0.64%
1-Year	-83.04%	+11.90%
3-Year	-96.15%	+48.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Beyond Air, Inc. (XAIR)

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Beyond Air Third Quarter 2025 Earnings: Beats Expectations

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Insider Stock Buying Reaches US$1.60m On Beyond Air

Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Performance Overview